Biotechnology Value Fund, L.P. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotechnology Value Fund, L.P.

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: sjemmeri who wrote (4506)	10/28/2005 10:55:46 AM
From: sjemmeri	Read Replies (3) of 4974

10:17 ABPI Accentia Biopharma IPO prices (8.00 ) Accentia Biopharma prices its IPO at $8. This biopharmaceutical co focuses on late-stage clinical products for respiratory disease and oncology. It has two product candidates entering or in Phase III clinical trials. First, SinuNase has been developed as a treatment for chronic sinusitis, a long-term inflammatory condition of the paranasal sinuses for which there is currently no FDA-approved therapy. SinuNase was accepted by the FDA in May 2005, and the co expects to initiate Phase III trials later this year. Second, Biovaxid is a patient-specific anti-cancer vaccine for the treatment of follicular non-Hodgkin's lymphoma. Biovaxid is currently in a pivotal Phase III clinical trial under an IND from the National Cancer Institute. In addition, the co has a growing specialty pharmaceutical business. The co is not profitable, but it posted sales for the 9 mos ending June of $17.7 mln, down 9% yoy... Briefing.com Note: Biotech IPOs have not been well received lately despite the BTK Index being up 21% since May. This is a small deal at 2.4 mln shares, led by Jefferies.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next